Prospects for passage of Democratic drug pricing legislation as part of the Build Back Better (BBB) Act dimmed again last week with news that Sen. Ben Ray Lujan (D-N.M.) had a stroke on Jan 27.
Lujan’s chief of staff
Category: Federal
The National Association of Community Health Centers (NACHC) told Republican members of Congress last week that “congressional action may be the only solution” to drug makers’ “aggressive actions to limit patients’ access to affordable medications at contract pharmacies.”
NACHC’s
Michelle Wiest, most recently vice president of pharmacy services at UC Health in Cincinnati, is Apexus’s new senior vice president of 340B policy and compliance.
Apexus announced Wiest’s hiring yesterday. The company said Wiest will oversee its education programming, compliance
…
340B covered entity allies in the U.S. House are booking an hour of floor speeches by members lauding the drug discount program next week Tuesday after all legislative business is finished.
Reps. Abigail Spanberger (D-Va.) and Dusty Johnson (R-S.D.) are
…
340B program federal administrators told health care providers attending the 340B Coalition winter conference in San Diego today that they are behind them in the battle with drug manufacturers over accessing 340B pricing in the contract pharmacy setting.
The U.S.
…Breaking News
Hospital Group Leader Says “We’re Prepared to Go” in Direction of Federal 340B Contract Pharmacy Legislation
For the first time since the 340B contract pharmacy impasse started over a year and a half ago, the leader of an influential hospital group said publicly today her association is prepared to move in the direction of a federal
…
A federal district judge on Friday granted the federal government’s motion to stay proceedings in drug industry vendor Kalderos’ 340B contract pharmacy suit.
The government had asked U.S. District Judge Dabney Friedrich of the District of Columbia to pause Kalderos’
…
340B Report Publisher and Chief Executive Officer Ted Slafsky says in his latest column for Omnicell’s blog that “all signs foretell a Republican takeover of the House and a very good possibility of the GOP assuming control of the closely
…
The U.S. Health Resources and Services Administration (HRSA) told drug manufacturer Celgene nearly five years ago the company “must ensure” that covered entities could buy its cancer drugs Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through Celgene’s limited
…
Health care services and group purchasing company Vizient asked Congress on Monday to pass the U.S. Senate version of bipartisan legislation to protect hospitals from losing their 340B eligibility due to changes in patient and payer mix caused by the
…